sting agonist diabzi  (MedChemExpress)

Journal: Materials Today Bio

Article Title: A photodynamically activated nanoplatform relieves glucose-driven immunosuppression to potentiate STING immunotherapy in triple-negative breast cancer

doi: 10.1016/j.mtbio.2026.103071

Figure Lengend Snippet: Characterization of DI/Ce6 and DI/Ce6@STF. (A, B) Representative electron microscopy images of DI/Ce6 and DI/Ce6@STF, respectively (scale bar: 100 nm); (C) Zeta potential of DI/Ce6 and DI/Ce6@STF; (D, E) Hydrodynamic particle size distributions of DI/Ce6 and DI/Ce6@STF measured by dynamic light scattering; (F) Particle size stability of DI/Ce6 and DI/Ce6@STF in PBS over 7 days; (G, H) Release Curves of DIABZI and STF-31 in DI/Ce6@STF; (I) Comparison of HPLC chromatograms for DI/Ce6@STF nanoparticles and free drug.

Article Snippet: STF-31 (HY-18728), DIABZI (HY-112921A) and Ce6(HY-13594) were all purchased from MedChemExpress (Shanghai, China).

Techniques: Electron Microscopy, Zeta Potential Analyzer, Comparison

Journal: Frontiers in Immunology

Article Title: STING inhibits viral lytic reactivation and cell growth in primary effusion lymphoma

doi: 10.3389/fimmu.2026.1823240

Figure Lengend Snippet: STING has variable protein expression in primary effusion lymphoma cells. RT-qPCR of (A) cGAS and (B) STING1 levels across eight KSHV-positive PEL cell lines and virus-negative lymphoma BJAB cells. Fold induction for each cell line is in comparison to BCBL1. All mRNA expression levels were normalized to GAPDH. (C) Western blot of total cGAS and STING protein levels across PEL cell lines. (D) Western blot detection of cGAS and total and phosphorylated STING and IRF3 (pIRF3) in BCBL1, BC1, BC2, BC3, BJAB cells 16 hours post-treatment with 4 µM diABZI. Data (A, B) are presented as mean ± SD.

Article Snippet: BCBL1 cells were treated with 2 μM diABZI STING agonist-1 [3HCL] prepared in PBS (MedChemExpress, #HY-112921B) for 24 hours prior to lytic induction.

Techniques: Expressing, Quantitative RT-PCR, Virus, Comparison, Western Blot

Journal: Frontiers in Immunology

Article Title: STING inhibits viral lytic reactivation and cell growth in primary effusion lymphoma

doi: 10.3389/fimmu.2026.1823240

Figure Lengend Snippet: STING agonist treatment inhibits KSHV lytic replication in BCBL1 and BCBL1-TRex-luciferase cells. (A) Experimental schematic for data shown in B–E . BCBL1 cells were treated with 2 µM diABZI for 24 hours prior to reactivation with NaB (1mM) and TPA (25 ng/mL). At 48 hours post-reactivation, mRNA expression of KSHV (B) immediate early gene ORF57 , (C) early gene ORF39 , and (D) late gene K8.1 were measured by RT-qPCR. (E) Western blot detection of KSHV protein ORF57 at 0 and 48 hours post-reactivation. (F) Experimental schematic for data shown in G–K, M . BCBL1-TRex-luciferase cells were treated with 5 µM diABZI for 24 hours prior to reactivation with doxycycline (1ug/mL). (G) Western blot for cGAS-STING activation (pTBK1, pIRF3) prior to reactivation. At 48 hours post-reactivation, mRNA expression of KSHV (H) immediate early gene ORF57 and (I) early gene ORF39 were measured by RT-qPCR. (J) At 48 hours post-reactivation, genomic DNA was extracted and measured for the number of KSHV ORF39 copies/mL by qPCR, normalized to genome β-actin copies. (K) Western blot detection of KSHV protein vIL6 (K2) at 0 and 48 hours post-reactivation. (L) BCBL1-TRex-luciferase cells were pretreated with 5 µM diABZI for 6 hours prior to reactivation. Equal volumes of supernatant were harvested at 72 hours post-reactivation and extracellular virion production was measured using the KSHV ORF39 gene. (M) RT-qPCR-based whole KSHV transcriptome array was performed. Higher transcript expression levels are indicated by red and lower expression levels by blue as shown in the key. All transcripts normalized to 18S rRNA. Data (B–D, H–J, L) are presented as mean ± SD. * indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001 by Student’s t-test.

Article Snippet: BCBL1 cells were treated with 2 μM diABZI STING agonist-1 [3HCL] prepared in PBS (MedChemExpress, #HY-112921B) for 24 hours prior to lytic induction.

Techniques: Luciferase, Expressing, Quantitative RT-PCR, Western Blot, Activation Assay

Journal: Frontiers in Immunology

Article Title: STING inhibits viral lytic reactivation and cell growth in primary effusion lymphoma

doi: 10.3389/fimmu.2026.1823240

Figure Lengend Snippet: Four PEL cell lines are sensitive to STING agonist treatment. CellTiter-Glo assay in (A) BCBL1, (C) BC1, (E) BC2, and (G) BCP1 cells treated with diABZI in a dose-dependent manner for 72 hours. Data are represented as percentage of relative luminescence compared to the mock condition. Live/dead cell counts in (B) BCBL1, (D) BC1, (F) BC2, and (H) BCP1 cells treated with diABZI in a dose-dependent manner for 72 hours. (I) Western blot of STING-TBK1-IRF3 activation after 16 hours of diABZI treatment. (J) Western blot of total capase-3 and cleaved caspase-3 following 4 hours of diABZI treatment. Data (A-H) are presented as mean ± SD of three independent biological repeats. ** indicates p<0.01; *** indicates p<0.001; **** indicates p<0.0001 by one-way ANOVA for CellTiter-Glo and Student’s t-test for live/dead cell counts.

Article Snippet: BCBL1 cells were treated with 2 μM diABZI STING agonist-1 [3HCL] prepared in PBS (MedChemExpress, #HY-112921B) for 24 hours prior to lytic induction.

Techniques: Glo Assay, Western Blot, Activation Assay

Journal: Frontiers in Immunology

Article Title: STING inhibits viral lytic reactivation and cell growth in primary effusion lymphoma

doi: 10.3389/fimmu.2026.1823240

Figure Lengend Snippet: STING loss- and gain- of function studies support a growth-restraining role in PEL. (A) BCBL1 and (B) BC3 cells were treated with 5 µM H151 for 72 hours and subjected to CellTiter-Glo assay. Western blot of STING overexpression 48 hours after electroporation of 100 ng pcDNA3.1 (EV) or 50-100 ng STING plasmid in (C) BCBL1 and (D) BC3 cells. CellTiter-Glo assay in (E) BCBL1 and (F) BC3 cells at 72 hours after EV or STING plasmid electroporation. Data is represented as relative luminescence units. Data (A-B, E-F) are presented as mean ± SD. * indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001 by Student’s t-test.

Article Snippet: BCBL1 cells were treated with 2 μM diABZI STING agonist-1 [3HCL] prepared in PBS (MedChemExpress, #HY-112921B) for 24 hours prior to lytic induction.

Techniques: Glo Assay, Western Blot, Over Expression, Electroporation, Plasmid Preparation